FDA committee recommends Siliq to provide Valeant welcome share boost

20 July 2016
valeant-big

Shares in Canadian drugmaker Valeant (TSX: VRX) took an upturn on Wednesday with the news that a US Food and Drug Administration advisory committee had voted unanimously in favor of approving Siliq (brodalumab) for adult patients with moderate-to-severe plaque psoriasis.

Valeant has had a miserable year, with allegations of unfair price hiking and 90% wiped off its share value since July 20, 2015, but its new chief executive Joseph Papa has promised a recovery, and the news on Siliq is a welcome boost.

A report presented to the FDA committee by agency staff had raised a few concerns about the treatment in relation to a potential link to suicidal behavior and major cardiovascular adverse events.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical